Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/2718| Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia. | |
| Rauch Bernhard. | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| 10.1177/2047487320920754 | |
| Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia. | |
| European journal of preventive cardiology | |
| 2020 | |
| Artículo | |
| https://journals.sagepub.com/doi/pdf/10.1177/2047487320920754 | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 1102454.pdf | 150.37 kB | Adobe PDF | Visualizar/Abrir |